Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -226.56% is 26% below its 1-year average of -179.47%, near the low end of its 1-year range (-236.10%–-110.36%).
As of the fiscal period ended Tuesday, June 30, 2026. 37.05% below its 12-month average of -165.31%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -226.56%.
RETURN ON EQUITY (ROE)
-226.56%
RETURN ON EQUITY (ROE) AVG TTM
-165.31%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-37.05%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.55%
median of 489 covered companies
CURRENT VS SECTOR MEDIAN
-487.71%
vs the sector median at left
CapsoVision, Inc.
Market Cap
$323.01M
Return on Equity (ROE)
-226.56%
TTM Avg
-165.31%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$316.53M
Return on Equity (ROE)
N/A
TTM Avg
30.84%
3Y Avg
30.84%
5Y Avg
30.84%
Market Cap
$328.40M
Return on Equity (ROE)
-41.02%
TTM Avg
-44.84%
3Y Avg
-46.96%
5Y Avg
-38.83%
Market Cap
$329.37M
Return on Equity (ROE)
-86.10%
TTM Avg
-112.93%
3Y Avg
-76.30%
5Y Avg
-62.48%
Market Cap
$309.45M
Return on Equity (ROE)
-16.18%
TTM Avg
-23.55%
3Y Avg
59.17%
5Y Avg
22.66%
Market Cap
$304.88M
Return on Equity (ROE)
-25.73%
TTM Avg
-32.35%
3Y Avg
-2448.72%
5Y Avg
-1749.34%
Market Cap
$341.50M
Return on Equity (ROE)
-26.14%
TTM Avg
-53.80%
3Y Avg
-12.25%
5Y Avg
19.21%
Market Cap
$341.46M
Return on Equity (ROE)
-320.77%
TTM Avg
-82.83%
3Y Avg
-78.63%
5Y Avg
-104.90%
Market Cap
$348.55M
Return on Equity (ROE)
N/A
TTM Avg
34.79%
3Y Avg
145.50%
5Y Avg
100.23%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CapsoVision, Inc. (CV) | $323.01M | -226.56% | -165.31% | N/A | N/A |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $316.53M | N/A | 30.84% | 30.84% | 30.84% |
| C4 Therapeutics, Inc. (CCCC)vs › | $328.40M | -41.02% | -44.84% | -46.96% | -38.83% |
| Cabaletta Bio, Inc. (CABA)vs › | $329.37M | -86.10% | -112.93% | -76.30% | -62.48% |
| Standard BioTools Inc. (LAB)vs › | $309.45M | -16.18% | -23.55% | 59.17% | 22.66% |
| Benitec Biopharma Inc. (BNTC)vs › | $304.88M | -25.73% | -32.35% | -2448.72% | -1749.34% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $341.50M | -26.14% | -53.80% | -12.25% | 19.21% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $341.46M | -320.77% | -82.83% | -78.63% | -104.90% |
| Agenus Inc. (AGEN)vs › | $348.55M | N/A | 34.79% | 145.50% | 100.23% |
| Embecta Corp. (EMBC)vs › | $354.48M | N/A | -12.63% | -14.73% | 14.28% |
ROE
-226.6%
ROA
-160.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -226.56% |
| 2026-03-31 | -133.40% |
| 2025-12-31 | -190.91% |
| 2025-09-30 | -110.36% |
| 2025-03-31 | -236.10% |
